Clinical impact of anti retroviral resistance testing: Current problems and future directions

International Journal of Antimicrobial Agents

Volumn 16, Issue 4, 2000, Pages 425-427

  Rusconi, Stefano ^a   Moroni, Mauro ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL TRIAL; ENZYME POLYMORPHISM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; MEDICAL DECISION MAKING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS LOAD;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; FORECASTING; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; PROGNOSIS;

EID: 0033664682     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(00)00271-5     Document Type: Article

References (24)

1. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
2. Maintenance anti-retroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy
3. Genotypic resistance analyses of plasma HIV-1 RNA in patients failing to the maintenance therapy in Trilege trial
4. Evolution of drug resistance associated with loss of viral suppression in patients treated with indinavir, lamivudine and zidovudine
5. Loss of anti-viral effect owing to zidovudine and lamivudine double resistance in HIV-1-infected patients in an ongoing open label trial
6. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors
7. Two distinct mutational pathways in HIV-1 RT confer zidovudine/lamivudine dual resistance
8. Lamivudine-resistant HIV-1 clinical isolates lacking the Met184Val mutation have novel polymorphism in RT
9. Constrained evolution of human immunodeficency virus type 1 protease during sequential therapy with two distinct protease inhibitors
10. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Anti-viral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome
11. Predictors of anti-viral response to saquinavir/ritonavir therapy in a clinical cohort who have failed prior protease inhibitors: A comparion of clinical characteristics, anti-retroviral drug history and HIV genotype
12. Baseline resistance profile predicts response to ritonavir/saquinavir therapy in a community setting
13. Correlation of virological response with genotype and phenotype of plasma HIV-1 variants in patients treated with nelfinavir in the US expanded access program
14. Prevalence of resistance-associated mutations in patients starting anti-virals: Virological response after approximately 1 year of therapy
15. Final results of CPCRA 046: A pilot study of anti-retroviral management based on plasma genotypic anti-retroviral resistance testing (GART) in patients failing anti-retroviral therapy
16. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
17. Reverse transcriptase and protease gene analysis at the time of primary HIV-1 infection
18. Transmission of HIV-1 resistant to multiple reverse transcriptase and protease inhibitors
19. Prevalence of drug-resistant HIV-1 variants of RT region and natural polymorphism in protease coding region of recently infected individuals
20. The spectrum and frequency of reduced anti-retroviral drug susceptibility with primary HIV infection in the United States
21. Predicting HIV-1 phenotypic resistance from genotype using a large phenotype-genotype relational database
22. Relationship of phenotypic and genotypic resistance profiles to virological outcome in a trial of abacavir, nelfinavir, efavirenz and adefovir dipivoxil in patients with virological failure receiving indinavir (ACTG 372)
23. Loss of lamivudine resistance in a zidovudine and lamivudine dual-resistant human immunodeficiency virus type 1 (HIV-1) isolate after discontinuation of in vitro lamivudine drug pressure
24. Anti-retroviral drug resistance testing in adults with HIV infection: Implications for clinical management